NCT00253513View on ClinicalTrials.gov

Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
LeukemiaMyelodysplastic Syndromes
Interventions
DRUG

fludarabine

30 mg/m2, IV for 5 days

DRUG

treosulfan

12 or 14 g/m2, IV for 5 days

PROCEDURE

allogeneic blood or bone marrow transplantation

bone marrow or peripheral blood stem cells

Trial Locations (3)

98109

Fred Hutchinson Cancer Research Center, Seattle

97239-3098

OHSU Knight Cancer Institute, Portland

98109-1023

Seattle Cancer Care Alliance, Seattle

All Listed Sponsors
collaborator

medac GmbH

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

OHSU Knight Cancer Institute

OTHER

NCT00253513 - Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome | Biotech Hunter | Biotech Hunter